Amgen, Inc. (AMGN) Stock Price Today
Aura AI Summary
Key Stats
- $196.55BMarket Cap
- -Volume
- HealthSector
- $388.1652W High
- $271.1852W Low
- -Typical Hold Time
- $241.83BEnterprise Value
- 2.77%Div Yield
- -Trading Activity
Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $388.16, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
GLP-1 receptor agonists linked to lower alcohol-related hospitalizations in adults with alcohol use disorder.
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
City Holding Co director buys 110 shares amid 11.27% YTD stock gain and steady dividends.
A director of City Holding Co increased their stake by purchasing 110 shares at $134.55 each, signaling confidence in the company. The stock has risen 11.27% year-to-date and is trading near its 52-week high, reflecting strong market performance. Cit...
Global AI in drug repurposing market to hit $10.56B by 2035, growing at 23.4% CAGR
The global AI in drug repurposing market, valued at $1.28 billion in 2025, is projected to reach $10.56 billion by 2035 with a CAGR of 23.4%. This growth is driven by the need to accelerate drug discovery, reduce costs, and address chronic and rare d...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.